Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

about

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.Clinical and Molecular Spectrum of Liposarcoma.

P2860

Q41550563-2603E32C-732A-4D44-863E-0E75F4E2CECD Q47315579-45EE331B-9943-47F9-B3CE-124CA84740C6

P2860

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

Item

http://www.wikidata.org/entity/Q37702556

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

@en

Molecular mechanism and therapeutic implications of selinexor

@nl

type

Item

label

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

@en

Molecular mechanism and therapeutic implications of selinexor

@nl

prefLabel

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

@en

Molecular mechanism and therapeutic implications of selinexor

@nl

P1476

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

@en

P2093

Anand Mayakonda

http://www.w3.org/2001/XMLSchema#string

Deepika Kanojia

http://www.w3.org/2001/XMLSchema#string

Erkan Baloglu

http://www.w3.org/2001/XMLSchema#string

H Phillip Koeffler

http://www.w3.org/2001/XMLSchema#string

Jonathan W Said

http://www.w3.org/2001/XMLSchema#string

Linda Shyue Huey Chuang

http://www.w3.org/2001/XMLSchema#string

Michael Kauffman

http://www.w3.org/2001/XMLSchema#string

Nachiyappan Venkatachalam

http://www.w3.org/2001/XMLSchema#string

Ngan B Doan

http://www.w3.org/2001/XMLSchema#string

Sharon Shacham

http://www.w3.org/2001/XMLSchema#string

P2860

Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region

Nuclear export of proteins and drug resistance in cancer

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

CRM1 is an export receptor for leucine-rich nuclear export signals

Cancer statistics, 2015

IGF binding proteins in cancer: mechanistic and clinical insights

CRM1 is responsible for intracellular transport mediated by the nuclear export signal

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

P304

7521-7532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.13485

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manoj Garg

P577

2016-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27893412

http://www.w3.org/2001/XMLSchema#string

P932

5352339

http://www.w3.org/2001/XMLSchema#string

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

about

P2860

P2860

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932